Leukemia Patient Cancer-Free After T-Cell Therapy

A 23-year-old woman appears to be free of leukemia following T-cell therapy.

Lynsie Conradi of Bellingham, Wash., had been diagnosed with acute lymphoblastic leukemia, a cancer that is generally highly treatable and curable. For a small percentage of patients, however, the disease is refractory to treatment and is fatal. Conradi's leukemia had relapsed twice.

Cancer trial at Seattle Children’s Hospital

She, therefore, entered a cellular immunotherapy Phase 1 cancer trial at Seattle Children’s Hospital. The trial is recruiting patients between 18 and 26 years of age with acute lymphoblastic leukemia that is refractory to treatment and who are believed to have a 20 percent chance of survival.

The trial involves taking a blood sample from the patient, reprogramming the infection-fighting T-cells to seek and destroy leukemia cells according to cell surface antigens, and then returning the blood to the patient's body.

"Results show that Lynsie has had a positive response to the T-cell therapy and, at this time, we do not detect any leukemia cells," said the trial's principal investigator.

Conradi's therapy is not finished, though. Now she must undergo a stem cell transplant, which will function as a sort of consolidation therapy to wipe her body entirely clean of any excess leukemia cells.

For information on the Phase 1 trial, call Seattle Children’s Cancer and Blood Disorders Center at 206-987-2106 or toll-free at 866-987-2000.

Source: Seattle Children's

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap